For adolescents with severe alopecia areata (AA), baricitinib is efficacious for hair regrowth, according to a study ...

A research group, led by Dr. Pavel Majer from IOCB Prague, in collaboration with the laboratories of Barbara Slusher and ...

For adults with severe alopecia areata (AA), ivarmacitinib, a selective Janus kinase 1 (JAK1) inhibitor, at doses of 4 and 8 mg is efficacious and tolerable.

In an alopecia areata trial, a novel bifunctional therapy that blocks signaling of the interleukin-7 and TSLP pathways ...

Bempikibart demonstrated positive, durable responses among patients with severe to very severe alopecia areata, according to ...

Thirty-six weeks of once-daily, oral baricitinib was associated with greater hair regrowth on the scalp, eyebrows and ...

Adolescents with alopecia areata achieve hair regrowth with 80% or more of scalp coverage while taking the Janus kinase inhibitor baricitinib, a phase 3 study finds.

The rising prevalence of prediabetes among young adults signals early metabolic dysfunction, significantly increasing the ...

STRATA Skin Sciences (SSKN) announces the results of a newly published study in Japan that further validates the technological advantages of ...

Significantly more patients receiving baricitinib 2 mg, 4 mg had SALT score ≤20, ≤10 versus placebo at week 36 ...

It’s time that insurance recognizes wigs as necessary medical expenses for those suffering from conditions like alopecia, ...